46 citations
,
February 2012 in “Oncology Reports” This review summarizes existing studies on sorafenib, noting its promising effects in some cancers, but also highlights its limitations and potential synergy when combined with other anticancer treatments.
9 citations
,
January 2018 in “Acta Clinica Croatica” This review suggests that bendamustine, alone or in combination, shows effectiveness in treating indolent non-Hodgkin lymphoma and chronic lymphocytic leukemia, with recent studies highlighting its benefits especially in combination therapies, while balancing efficacy with a favorable toxicity profile.
1 citations
,
May 2022 in “European Journal of Dermatology” This study found that while no predictive factors for response to vismodegib were identified, longer treatment duration was associated with a lower risk of relapse in basal cell carcinoma patients.
2 citations
,
December 2020 in “JAMA Dermatology” In this study, the incidence of androgenic alopecia among transgender patients increased after starting masculinizing hormone therapy, with the highest incidence observed in the fourth year of treatment.
February 2024 in “Frontiers in Cell and Developmental Biology” This study found that eribulin-based chemotherapy resulted in longer median progression-free and overall survival, with fewer side effects, for advanced triple-negative breast cancer patients compared to other chemotherapy options.